@article{oai:nagasaki-u.repo.nii.ac.jp:00016409,
 author = {Ikeda, Maho and Takeshima, Fuminao and Isomoto, Hajime and Shikuwa, Saburo and Mizuta, Yohei and Ozono, Yoshiyuki and Kohno, Shigeru},
 issue = {7},
 journal = {Digestive diseases and sciences},
 month = {Jul},
 note = {PURPOSE: To determine whether simvastatin is able to inhibit inflammation in trinitrobenzene sulfonic acid (TNBS)-induced or oxazalone (OXA)-induced colitis. RESULTS: In the prophylactic protocol, simvastatin dose-dependently suppressed the decrease in body weight and inflammatory grade of TNBS-treated mice. In contrast, in the therapeutic protocol, no significant difference in body weight reduction was observed between simvastatin-treated and control mice. IFN-gamma release from LP cells was significantly suppressed in mice receiving high-dose simvastatin in the prophylactic protocol. In contrast to TNBS colitis, even high-dose prophylactic simvastatin had no suppressive effects on either weight reduction or the inflammatory grade in OXA colitis. CONCLUSION: Our results indicate that simvastatin negatively regulates inflammation in TNBS-induced colitis, but not in OXA-induced colitis. In TNBS-induced colitis, simvastatin suppressed the Th1-polarized immune response. Our findings suggest that simvastatin has potential effects as a therapeutic agent in human inflammatory bowel disease, particularly Crohn's disease., Digestive diseases and sciences, 53(7), pp.1869-1875; 2008},
 pages = {1869--1875},
 title = {Simvastatin attenuates trinitrobenzene sulfonic acid-induced colitis, but not oxazalone-induced colitis.},
 volume = {53},
 year = {2008}
}